


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of the Claims:**

1-26. Canceled.

27. (new) A method of treating, preventing, modifying or managing pain, which comprises administering to a patient a therapeutically or prophylactically effective amount of a compound of formula:



in which


Y is oxygen or H<sub>2</sub>,

a first of R<sup>1</sup> and R<sup>2</sup> is halo, alkyl, alkoxy, alkylamino, dialkylamino, cyano, or carbamoyl, the second of R<sup>1</sup> and R<sup>2</sup>, independently of the first, is hydrogen, halo, alkyl, alkoxy, alkylamino, dialkylamino, cyano, or carbamoyl, and

R<sup>3</sup> is hydrogen, alkyl, or benzyl;

or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

28. (new) A method of treating, preventing, modifying or managing pain, which comprises administering to a patient a therapeutically or prophylactically effective amount of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline having the formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

29. (new) The method of claim 27 or 28, wherein the compound is 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline.

30. (new) The method of claim 27 or 28, wherein the compound is a pharmaceutically acceptable salt.

31. (new) The method of claim 27 or 28, wherein the compound is a pharmaceutically acceptable solvate.

32. (new) The method of claim 27 or 28, wherein the compound is a pharmaceutically acceptable stereoisomer.

33. (new) The method of claim 32, wherein the stereoisomer is an enantiomerically pure R isomer.

34. (new) The method of claim 32, wherein the stereoisomer is an enantiomerically pure S isomer.

35. (new) The method of claim 27 or 28, which further comprises administering a therapeutically or prophylactically effective amount of a second active agent.

36. (new) The method of claim 35, wherein the second active agent is an antidepressant, antihypertensive, anxiolytic, calcium channel blocker, alpha-adrenergic receptor agonist, alpha-adrenergic receptor antagonist, ketamine, anesthetic, muscle relaxant, non-narcotic analgesic, opioid analgesic, anti-inflammatory agent, immunomodulatory agent, immunosuppressive agent, corticosteroid, anticonvulsant, cox-2 inhibitor, hyperbaric oxygen, or a combination thereof.

37. (new) The method of claim 35, wherein the second active agent is salicylic acid acetate, celecoxib, ketamine, gabapentin, carbamazepine, oxcarbazepine, phenytoin, sodium valproate, prednisone, nifedipine, clonidine, oxycodone, meperidine, morphine sulfate, hydromorphone, fentanyl, acetaminophen, ibuprofen, naproxen sodium, griseofulvin, amitriptyline, imipramine or doxepin.

38. (new) The method of claim 27 or 28, wherein the pain is nociceptive pain or neuropathic pain.

39. (new) The method of claim 27 or 28, wherein the pain is associated with chemical or thermal burn, cut of the skin, contusion of the skin, osteoarthritis, rheumatoid arthritis, tendonitis, or myofascial pain.

40. (new) The method of claim 27 or 28, wherein the pain is diabetic neuropathy, post herpetic neuralgia, trigeminal neuralgia, post-stroke pain, complex regional pain syndrome, sympathetic maintained pain syndrome, reflex sympathetic dystrophy, reflex neurovascular dystrophy, reflex dystrophy, spinal cord injury pain, Sudeck atrophy of bone, algoneurodystrophy, shoulder hand syndrome, post-traumatic dystrophy, cancer related pain, phantom limb pain, fibromyalgia, chronic fatigue syndrome, radiculopathy, luetic neuropathy, or painful neuropathic condition induced from a drug.

41. (new) The method of claim 40, wherein the complex regional pain syndrome is type I or type II.

42. (new) The method of claim 40, wherein the painful neuropathic condition is iatrogenically induced by vincristine, velcade or thalidomide.

43. (new) The method of claim 27 or 28, wherein the pain is visceral pain, migraine, tension- type headache, post-operative pain, or mixed pain of nociceptive and neuropathic pain.

44. (new) The method of claim 27 or 28, wherein the compound is administered orally.

45. (new) The method of claim 44, wherein the compound is administered in the form of a capsule or tablet.

46. (new) The method of claim 27 or 28, wherein the compound is administered in an amount of from about 0.1 to about 150 mg per day.

47. (new) The method of claim 28, wherein the compound is administered in an amount of from about 0.1 to about 40 mg per day.

48. (new) The method of claim 47, wherein the compound is administered in an amount of from about 0.5 to about 25 mg per day.

49. (new) The method of claim 47, wherein the compound is administered in an amount of from about 2 to about 10 mg per day.

50. (new) The method of claim 47, wherein the compound is administered in an amount of about 5 mg per day.